Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer

NCT00072566 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

NIH

Sponsor class

Conditions

Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Stage IV Ovarian Cancer

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Cyclophosphamide
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)